Vilin Bio Med Limited (NSE:VILINBIO)
India · Delayed Price · Currency is INR 44.35
-0.85 (-1.88%)
Jun 17, 2026, 11:14 AM IST
Vilin Bio Med Revenue
In the fiscal year ending March 31, 2026, Vilin Bio Med had annual revenue of 422.63M INR with 185.37% growth. Vilin Bio Med had revenue of 325.99M in the half year ending March 31, 2026, with 289.22% growth.
Revenue
422.63M
Revenue Growth
+185.37%
P/S Ratio
1.46
Revenue / Employee
n/a
Employees
n/a
Market Cap
618.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 422.63M | 274.53M | 185.37% |
| Mar 31, 2025 | 148.10M | -9.95M | -6.30% |
| Mar 31, 2024 | 158.05M | 34.68M | 28.11% |
| Mar 31, 2023 | 123.37M | 11.18M | 9.97% |
| Mar 31, 2022 | 112.19M | -5.00M | -4.26% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Remus Pharmaceuticals | 8.54B |
| Accent Microcell | 3.56B |
| Zenith Drugs | 1.76B |
| Infinium Pharmachem | 1.57B |
| Quest Laboratories | 1.26B |
| Sotac Pharmaceuticals | 1.02B |
| Sunrest Lifescience | 708.33M |
| Medicamen Organics | 226.30M |